Research & Development
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention
3 November 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that it has initiated ENHANCE-3, a Phase 3 clinical trial evalua...
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
3 November 2026 - Swedish oncology-focused development company Vivesto AB (STO:VIVE) said on Tuesday that it has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) f...
Lupin's Amifampridine Tablets approved by US FDA
3 November 2026 - India-based global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Monday that it has received approval from the US Food and Drug Administration (FDA) for ...
Roche wins FDA clearance for customisable respiratory pathogen test
2 November 2026 - Healthcare company Roche (SIX: RO, ROP) (OTCQX: RHHBY) announced on Monday that it has received US Food and Drug Administration 510(k) clearance for its cobas eplex respiratory patho...
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
2 November 2026 - INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercialising DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectiou...
Immunome secures EMA validation of varegacestat application for desmoid tumors
30 October 2026 - Biotechnology company Immunome Inc (Nasdaq:IMNM) announced on Friday that the European Medicines Agency (EMA) has validated its Marketing Authorization Application for varegacestat, ...